| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Institute of Cancer Research, Haddow Laboratories, Surrey SM2 5NG, United Kingdom [W. D., A. H., D. H. P.]; INSERM U488, 80 rue de Général Leclerc, Hôpital de Bicêtre, F-94276 Le Kremlin-Bicêtre, France [K. M. R.]; and Department of Toxicology, German Institute of Human Nutrition, D-14558 Potsdam-Rehbrücke, Germany [W. M., H. R. G.]
Previous work has indicated that metabolic activation of tamoxifen in
rat liver cells involves cytochrome P450-mediated
-hydroxylation,
followed by sulfate ester formation, mediated by hydroxysteroid
sulfotransferase a (rHSTa), a member of the SULT2A
subfamily, which efficiently metabolizes dehydroepiandrosterone.
Because it is known that the expression of rHSTa and other SULT2A forms
is substantially higher in female rats than in males, it might be
predicted that tamoxifen would be a more potent liver carcinogen in
females than in males. Yet tamoxifen has been shown to be equipotent in
both sexes. To investigate this paradox, primary cultures of
hepatocytes were prepared from Fischer F-344 rats and treated with
tamoxifen (10 µM) or
-hydroxytamoxifen (1
µM). Rats were also treated with tamoxifen daily by
gavage (0.12 mmol/kg/day) for up to 14 days. DNA was isolated from
hepatocytes and liver and analyzed by 32P-postlabeling.
Liver cytosol fractions were prepared and analyzed for
dehydroepiandrosterone sulfotransferase activity and SULT2A protein
levels. In tamoxifen-treated hepatocytes and after a single dose of
tamoxifen in vivo, DNA adduct formation in male cells
was significantly lower than in female cells, 11- and 6-fold,
respectively. However, with increasing daily doses of rats with
tamoxifen, the adduct level in males increased to a level 89% of that
in females by 14 days. Dehydroepiandrosterone sulfotransferase activity
in male rat liver cytosols was only 17% of the activity of female
cytosols after one dose of tamoxifen but 64% after 14 days of exposure
to the compound. This increase in activity correlated with increases in
the levels of SULT2A protein, detected by Western blotting. Western
blotting did not allow the unambiguous identification of the induced
SULT2A form(s). However, by using a specific reverse transcriptase/PCR
technique, it was found that it was primarily rHSTa that was induced.
Thus, after prolonged exposure to tamoxifen, DNA adduct formation and
rHSTa expression in males are significantly closer to the levels in
females than they are after initial exposure. These changes explain the
similar susceptibility of male and female rats to tamoxifen
carcinogenesis.
This article has been cited by other articles:
![]() |
D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods Mutagenesis, March 1, 2005; 20(2): 115 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Fang, M. Abdolalipour, Z. Duanmu, J. R. Smigelski, A. Weckle, T. A. Kocarek, and M. Runge-Morris REGULATION OF GLUCOCORTICOID-INDUCIBLE HYDROXYSTEROID SULFOTRANSFERASE (SULT2A-40/41) GENE TRANSCRIPTION IN PRIMARY CULTURED RAT HEPATOCYTES: ROLE OF CCAAT/ENHANCER-BINDING PROTEIN LIVER-ENRICHED TRANSCRIPTION FACTORS Drug Metab. Dispos., January 1, 2005; 33(1): 147 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Beland, M. I. Churchwell, D. R. Doerge, D. R. Parkin, D. Malejka-Giganti, A. Hewer, D. H. Phillips, P. L. Carmichael, G. Gamboa da Costa, and M. M. Marques Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in Humans J Natl Cancer Inst, July 21, 2004; 96(14): 1099 - 1104. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Maiti and G. Chen Tamoxifen Induction of Aryl Sulfotransferase and Hydroxysteroid Sulfotransferase in Male and Female Rat Liver and Intestine Drug Metab. Dispos., May 1, 2003; 31(5): 637 - 644. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats Carcinogenesis, March 1, 2002; 23(3): 491 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |